Description: Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Home Page: www.artivabio.com
5505 Morehouse Drive
San Diego,
CA
92121
United States
Phone:
858 267 4467
Officers
| Name | Title |
|---|---|
| Dr. Fred Aslan M.D. | President, CEO & Director |
| Dr. Peter Flynn Ph.D. | Co-Founder & Strategic Advisor |
| Ms. Jennifer Kinsbruner Bush Esq., J.D. | Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer |
| Mr. Christopher P. Horan | Chief Technical Operations Officer |
| Ms. Neha Krishnamohan | CFO & Executive VP of Corporate Development |
| Dr. Thorsten Graef M.D., Ph.D. | Chief Medical Officer |
| Dr. Heather Raymon Ph.D. | Senior Vice President of Research & Early Development |
| Mr. Javier Coindreau M.D. | Senior VP of Medical Affairs |
| Dr. David Moriarty Ph.D. | Senior VP of Clinical Operations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2906 |
| Price-to-Sales TTM: | 108.6995 |
| IPO Date: | 2024-07-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 82 |